Targeted therapy for triple-negative breast cancer using antibody-drug conjugates
Official title: Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
Funded at University of Alabama at Birmingham · NIH-11001831 · Data updated 2026-11-12
This study is working on new treatments for triple-negative breast cancer that aim to target cancer cells directly while being kinder to healthy cells, so patients can have better outcomes with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | January 1, 2020 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $85,364 |
| NIH project number | 5R01CA238273-06 |
| Project ID | NIH-11001831 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded well to standard treatments.
✕Less likely to help
Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on developing targeted therapies specifically for triple-negative breast cancer (TNBC), a type of breast cancer known for its aggressive nature and poor prognosis. The approach involves creating antibody-drug conjugates (ADCs) that can selectively target cancer cells while minimizing damage to normal cells. By identifying specific surface receptors on TNBC cells, the researchers aim to design therapies that effectively eliminate cancer cells with fewer side effects. The study includes both laboratory and animal model evaluations to assess the safety and effectiveness of these novel treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatment options for patients with triple-negative breast cancer.
How similar studies have gone: Previous research has shown promise in using targeted therapies for other types of cancers, indicating potential success for this novel approach in TNBC.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Liu, Runhua Runa — University of Alabama at Birmingham
- Study coordinator: Liu, Runhua Runa
Related research
Other NIH-funded projects on the same topics.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Improving Targeted Therapy for Triple Negative Breast Cancer
This project aims to develop a new way to deliver targeted medicines directly to triple-negative breast cancer tumors using special RNA molecules.
-
Using PET imaging to understand glutamine metabolism in triple-negative breast cancer
This study is looking at how a substance called glutamine affects triple-negative breast cancer to find better ways to treat it, using special imaging to see how much glutamine is in the cancer cells and helping doctors choose the best therapies for patients.
-
New treatment approach for triple negative breast cancer using targeted siRNA delivery
This study is testing a new way to deliver a special treatment directly to tumors in patients with triple negative breast cancer, making it easier for the medicine to reach the cancer and potentially improve how well it works.
-
Targeted therapy for aggressive breast cancer
This study is testing a new treatment for triple-negative breast cancer that uses tiny particles to deliver medicine directly to cancer cells, helping to stop them from spreading and improving how well the treatment works.
-
Using nanotechnology to target therapy for triple negative breast cancer
This study is exploring new ways to treat triple negative breast cancer using tiny particles to deliver special molecules that can help stop cancer cells from growing, aiming to create better treatment options that work specifically for this type of cancer and have fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.